Clinical Reviews in Allergy & Immunology

, Volume 38, Issue 1, pp 32–38

Pathogenesis of Hyper IgE Syndrome

  • Jennifer Heimall
  • Alexandra Freeman
  • Steven M. Holland
Article
  • 1.1k Downloads

Abstract

Hyper IgE syndrome (HIES) is a rare primary immunodeficiency characterized by the triad of elevated IgE and eosinophilia, eczema, and recurrent skin and pulmonary infections. The autosomal dominant (AD) form of HIES results from mutations in STAT3 and is characterized by disordered inflammation, connective tissue, and skeletal abnormalities. Tissue-specific STAT3 deficiency in animals, cytokine and transcriptional array data, and careful clinical phenotyping have explained some of the pathophysiology of the immunologic and non-immunologic abnormalities of AD-HIES. In depth study of the role of STAT3 mutations in specific aspects of HIES may lead to better understanding and new approaches to treatment of conditions intrinsic to HIES that are common in the general population, such as staphylococcal infections, scoliosis, osteoporosis, bronchiectasis, and arterial aneurysms. As the genotypes of STAT3 deficiency are further characterized, genotype–phenotype correlations may emerge that will be informative regarding specific molecular interactions. Autosomal recessive forms of hyper IgE (AR-HIES) have also been reported. A single case of homozygous deficiency of the signal protein Tyk2 has been reported as well as a recessive syndrome with some features overlapping AD-HIES, but for which the genetic etiology is unknown. Better understanding of the pathophysiology and mechanisms of dominant and recessive hyper IgE syndromes will shed light on somatic and immune biology and may improve quality of life and survival for HIES patients.

Keywords

Hyper IgE syndrome STAT3 Autosomal dominant IL-17 Scoliosis Aneurysms 

References

  1. 1.
    Buckley RH, Wray BB, Belmaker EZ (1972) Extreme hyperimmunologlobulinemia E and undue susceptibility to infection. Pediatrics 49:59–70PubMedGoogle Scholar
  2. 2.
    Davis SD, Wedgwood RJ (1966) Job’s syndrome: recurrent, “cold”, staphylococcal abscesses. Lancet 1:1013–1015CrossRefPubMedGoogle Scholar
  3. 3.
    Buckley RH (2001) The Hyper-IgE syndrome. Clin Rev Allergy Immunol 20:139–154CrossRefPubMedGoogle Scholar
  4. 4.
    Grimbacher B, Holland SM, Gallin JI et al (1999) Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N. Engl J Med 340:692–702CrossRefPubMedGoogle Scholar
  5. 5.
    Holland S, DeLeo F, Elloumi H et al (2007) STAT3 mutations in the hyper-IgE syndrome. NEJM 357(16):1608–1619CrossRefPubMedGoogle Scholar
  6. 6.
    Minegishi Y, Saito M, Tsuchiya S (2007) Dominant negative mutations in the DNA binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058–1062CrossRefPubMedGoogle Scholar
  7. 7.
    Freeman A, Kleiner D, Nadiminti H et al (2007) Causes of death in hyper IgE syndrome. JACI 119:1234–1240Google Scholar
  8. 8.
    Chamlin SL, McCalmont TH, Cunningham BB, Esterly NB, Lai CH et al (2002) Cutaneous manifestations of hyper-IgE syndrome in infants and children. J Pediatr 141:572–575CrossRefPubMedGoogle Scholar
  9. 9.
    Eberting CL, Davis J, Puck JM, Holland SM (2004) Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol 140:1119–1125CrossRefPubMedGoogle Scholar
  10. 10.
    Freeman AF, Davis J, Anderson VL, Barson W, Darnell DN, Puck JM, Holland SM (2006) Pneumocystis jiroveci infection in patients with hyper-immunoglobulin E syndrome. Pediatrics 118:e1271–e1275CrossRefPubMedGoogle Scholar
  11. 11.
    Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JL (1988) Cryptococcosis of the colon resembling Crohn’s disease in a patient with the hyperimmunoglobulinemia E syndrome. Gastroenterology 94:808–812PubMedGoogle Scholar
  12. 12.
    Jacobs DH, Macher AM, Handler R, Bennett JE, Collen MJ, Gallin JI (1984) Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job’s) syndrome. Gastroenterology 87:201–203PubMedGoogle Scholar
  13. 13.
    Domingo D, Freeman AF, Davis J, Puck JM, Tianxia W, Holland SM, Hart TC (2007) Novel intraoral phenotypes in hyper Immunoglobulin E syndrome. Oral Diseases 14:73–81Google Scholar
  14. 14.
    O’Connell AC, Puck JM, Grimbacher B, Facchetti F, Majorana A, Gallin JI, Malech HL, Holland SM (2000) Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:177–185CrossRefPubMedGoogle Scholar
  15. 15.
    Ling JC, Freeman AF, Gharib AM, Arai AE, Lederman RJ, Rosing DR, Holland SM (2007) Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol 122:255–258CrossRefPubMedGoogle Scholar
  16. 16.
    Young TY, Jerome D, Gupta S (2007) Hyperimmunoglobulinemia E syndrome associated with coronary artery aneurysms: deficiency of central memory CD4+ T cells and expansion of effector memory CD4+ T cells. Ann Allergy Asthma Immunol 98:389–392PubMedCrossRefGoogle Scholar
  17. 17.
    Freeman AF, Collura-Burke CJ, Patronas NJ, Ilcus LS, Darnell D, Davis J, Puck JM, Holland SM (2007) Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics 119:e1121–e1125CrossRefPubMedGoogle Scholar
  18. 18.
    Hoger PH, Boltshauser E, Hitzig WH (1985) Craniosynostosis in hyper-IgE syndrome. Eur J Pediatr 144:414–417CrossRefPubMedGoogle Scholar
  19. 19.
    Smithwick EM, Finelt M, Pahwa S, Good RA, Naspitz CK, Mendes NF et al (1978) Cranial synostosis in Job’s syndrome. Lancet 15:826CrossRefGoogle Scholar
  20. 20.
    Grimbacher B, Schaffer AA, Holland SM, Davis J, Gallin JI, Malech HL, Atkinson TP, Belohradksy BH, Buckley RH, Cossu F, Espanol T, Garty BZ, Metamoros N, Myers LA, Nelson RP, Ochs HD, Renner ED, Wellinghausen N, Puck JM (1999) Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 65:735–744CrossRefPubMedGoogle Scholar
  21. 21.
    Leonard GD, Posadas E, Herrmann PC et al (2004) Non-Hodgkin’s lymphoma in Job’s syndrome: a case report and review of the literature. Leuk Lymphoma 45:2521–2525CrossRefPubMedGoogle Scholar
  22. 22.
    Levy DE, Lee C (2002) What does Stat3 do? J Clin Invest 109:1143–1148PubMedGoogle Scholar
  23. 23.
    Renner E, Rylaarsdam S, Anover-Sombke S et al (2008) Novel signal transducer and activator of transcription 3 mutations, reduced Th17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. JACI 122:181–187Google Scholar
  24. 24.
    Borish L, Steinke J (2003) Cytokines and chemokines. JACI 111:S460–S475Google Scholar
  25. 25.
    Commins S, Steinke J, Borish L (2008) The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, IL-29. JACI 121(5):1108–1111Google Scholar
  26. 26.
    Milner J, Brenchley J, Laurence A et al (2008) Impaired Th17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 252:773–776 This is the first study to demonstrate that persons with HIES lack IL17-producing T cells and that their T cells are unable to be differentiated to produce Th17 cells in vitroCrossRefGoogle Scholar
  27. 27.
    Beaucoudrey L, Puel A, Filpe-Santos O et al (2008) Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing cells. J Exp Med 205:1543–1550CrossRefPubMedGoogle Scholar
  28. 28.
    Harris T, Grosso J, Yen H et al (2007) An in vivo requirement for STAT3 signaling in Th17 development and Th17 dependant autoimmunity. J Immunol 179:4313–4317PubMedGoogle Scholar
  29. 29.
    Ma C, Chew G, Simpson N et al (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205:1551–1557CrossRefPubMedGoogle Scholar
  30. 30.
    Aujla SH, Chan YR, Zheng M et al (2008) IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med 14:275–281CrossRefPubMedGoogle Scholar
  31. 31.
    Dong C (2008) Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8:337–348CrossRefPubMedGoogle Scholar
  32. 32.
    Huang W, Na L, Fidel PL, Schwarzenberger P (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190:624–631CrossRefPubMedGoogle Scholar
  33. 33.
    Kao CY, Chen Y, Thai P et al (2004) IL-17 markedly up-regulates Beta-defensin-2 expression in human airway epithelium via JAK and NF-kB signaling pathways. J Immunol 173:3482–3491PubMedGoogle Scholar
  34. 34.
    Schnyder-Candrian S et al (2006) Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 203:2715–2725CrossRefPubMedGoogle Scholar
  35. 35.
    Ozaki K et al (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630–1634CrossRefPubMedGoogle Scholar
  36. 36.
    Avery D, Ma C, Bryant V et al (2008) STAT3 is required for IL-21 induced secretion of IgE from human naïve B cells. Blood 112:1784–1793CrossRefPubMedGoogle Scholar
  37. 37.
    Wolk K, Kunz S, Witte E et al (2004) IL-22 increases the innate immunity of tissues. Immunity 21:241–254CrossRefPubMedGoogle Scholar
  38. 38.
    Yeganeh M, Henneke P, Rezaei N et al (2008) Toll-like receptor stimulation induces higher TNF-a secretion in peripheral blood mononuclear cells from patients with hyper IgE syndrome. Int Arch Allergy Immunol 146:190–194CrossRefPubMedGoogle Scholar
  39. 39.
    Takeda K, Clausen BE, Kaisho T et al (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39–49CrossRefPubMedGoogle Scholar
  40. 40.
    Takeda K, Noguchi K, Shi W et al (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 94:3801–3804CrossRefPubMedGoogle Scholar
  41. 41.
    Hokuto I, Ikegami M, Yoshida M et al (2004) Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 113:28–37PubMedGoogle Scholar
  42. 42.
    Zhang A, Welte T, Troiano N et al (2005) Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem Biophys Res Comm 328:800–807CrossRefPubMedGoogle Scholar
  43. 43.
    Leung DY, Key L, Steinberg JJ, Young MC, Von Deck M, Wilkinson R, Geha R (1988) Increased in vitro bone resorption by monocytes in the hyper-immunologulin E syndrome. J Immunol 140:84–88PubMedGoogle Scholar
  44. 44.
    Datta HK, Ng WF, Walker JA et al (2008) The cell biology of bone metabolism. J Clin Pathol 61:577–587CrossRefPubMedGoogle Scholar
  45. 45.
    Duplomb L, Baud’huin M, Charrier C et al. (2008) IL-6 inhibits RANKL-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of STAT3. Endocrinology. doi:10.1210/en.2007-1719
  46. 46.
    Okada S, Nakamura M, Katoh H et al (2006) Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 12:829–834CrossRefPubMedGoogle Scholar
  47. 47.
    Hilfiker-Kleiner D, Hilfiker A, Fuchs M et al (2004) Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition and heart protection from ischemic injury. Circ Res 95(2):187–195CrossRefPubMedGoogle Scholar
  48. 48.
    Scarabelli T, Townsend P, Scarabelli C et al (2008) Amino acid supplementation differentially modulates STAT1 and STAT3 activation in the myocardium exposed to ischemia/reperfusion injury. Am J Cardiol 101:63E–68ECrossRefPubMedGoogle Scholar
  49. 49.
    Olive M, Mellad JA, Beltran LE, Ma M, Cimato T, Noguchi AC, San H, Childs R, Kovacic JC, Boehm M (2008) p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. J Clin Invest 118:2050–2061PubMedGoogle Scholar
  50. 50.
    Sano S, Itami S, Takeda K et al (1999) Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18:4657–4668 30. Welte TCrossRefPubMedGoogle Scholar
  51. 51.
    Renner E, Puck J, Holland S et al (2004) Autosomal recessive hyperimmunoglobulin E Syndrome: a distinct disease entity. J Pediatr 144:93–99CrossRefPubMedGoogle Scholar
  52. 52.
    Minegishi Y, Saito M, Morio T et al (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745–755CrossRefPubMedGoogle Scholar
  53. 53.
    Woellner C, Schaffer A, Puck J (2007) The hyper IgE syndrome and mutations in TYK2. Immunity 26:535CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Jennifer Heimall
    • 1
  • Alexandra Freeman
    • 2
  • Steven M. Holland
    • 1
  1. 1.Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA
  2. 2.SAIC-Frederick, IncNCI-FrederickFrederickUSA

Personalised recommendations